Chengyi Pharmaceutical released its 2026 interim report. The company's total operating revenue was 432 million yuan, and net profit attributable to the parent company was 94.8687 million yuan, a decrease of 15.61% compared with the same period last year. Net cash inflow from operating activities was 141 million yuan, down 0.28% year-on-year. The company's latest asset-liability ratio was 18.49%, gross margin was 70.83%, ROE was 6.68%, and diluted earnings per share was 0.21 yuan, down 16.00% year-on-year. The number of shareholders was 20,700, and the top ten shareholders held 38.49% of the total share capital.
Zhejiang Cheng Yi Pharmaceutical Co LtdNet profit fell 15.61% year-on-year in the interim report.
